Premium
Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus‐related hepatocellular carcinoma
Author(s) -
Tomimaru Yoshito,
Nagano Hiroaki,
Eguchi Hidetoshi,
Kobayashi Shogo,
Marubashi Shigeru,
Wada Hiroshi,
Tanemura Masahiro,
Umeshita Koji,
Hiramatsu Naoki,
Takehara Tetsuo,
Doki Yuichiro,
Mori Masaki
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21633
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , hepatitis c virus , interferon , hepatectomy , multivariate analysis , antiviral therapy , hepatitis c , immunology , surgery , virus , chronic hepatitis , resection
Background and Objectives Interferon (IFN) can eradicate hepatitis C virus (HCV)‐RNA from serum and hepatic tissue, and suppress the development of hepatocellular carcinoma (HCC). Despite such effectiveness, HCC develops even in HCV patients successfully treated with IFN therapy. Methods HCV‐related HCC patients who underwent curative hepatectomy for HCC were divided into three groups according to preceding IFN for HCV infection therapy and the therapeutic effect: responders group (n = 23), non‐responders group (n = 46), and no‐IFN group (n = 215). Postoperative outcome was retrospectively examined in the three groups. Results AST and ALT were significantly lower in responders group than non‐responders group ( P < 0.001, P = 0.001) and no‐IFN group ( P = 0.001, P = 0.002). Platelet count was significantly higher in responders group than other groups ( P = 0.008, P = 0.001). The percentage of cirrhotic patients in responders group was significantly lower than other groups ( P = 0.017, P = 0.014). Multivariate analysis identified preceding IFN therapy to be associated with disease‐free survival at marginal significance ( P = 0.086), and as a significant independent factor for overall survival ( P = 0.042). Conclusions Preceding IFN therapy for HCV infection improves postoperative outcome in HCV‐related HCC patients treated successfully with IFN. J. Surg. Oncol. 2010;102:308–314. © 2010 Wiley‐Liss, Inc.